Ramelteon Intermediate 12 CAS 1053239-39-6 Maʻemaʻe >98.0% (HPLC)

2-(2,6,7,8-Tetrahydro-1H-Indeno[5,4-b]furan-8-yl)ethanamine Hydrochloride (CAS: 1053239-39-6) he mea waena o Ramelteon (CAS: 196597- 26-9).ʻAʻole like me ka hapa nui o ka mālama ʻana i ka insomnia e kuhikuhi ana i ka GABA (g-aminobutyric acid) receptor complex, ʻo Ramelteon kahi agonist o ka melatonin receptor.ʻO ka mea kūikawā, he kiʻekiʻe kona koho no ka MT1 a me MT2 subtypes, i hoʻopili ʻia i ka mālama ʻana i nā mele circadian, ma luna o ka mea loaʻa MT3 kuleana no nā hana melatonin ʻē aʻe.ʻO ka nele o ka pilina no ka GABA receptor complex akā pū kekahi neurotransmitter, dopaminerigic, opiate, a me benzodiazepine receptors e hōʻike ana i kahi kūlana palekana maikaʻi ʻole me ka hiki ʻole o ka hōʻino ʻana i nā lāʻau hypnotic e kuhikuhi ana i kēia mau mea loaʻa.No laila, ʻaʻole ʻo Ramelteon kahi lāʻau i hoʻonohonoho ʻia.ʻO nā metabolites mua ka hydroxylation a me ka oxidation i nā ʻano carbonyl me nā metabolites lua ma muli o ka glucuronidation.No ka mea ʻo CYP1A2 ka isozyme koʻikoʻi e pili ana i ka metabolism hepatic o Ramelteon, ʻaʻole pono e lawe pū ʻia me nā inhibitors CYP1A2 ikaika, e like me ka fluvoxamine.ʻO ka hui pū ʻana me ka ketoconazole (kahi CYP3A4 inhibitor) a i ʻole fluconazole (he mea hoʻopaneʻe ikaika CYP2C9) i hopena i ka piʻi nui o ka AUC a me Cmax, akā ʻo ka nui o ka metabolism a me nā ʻano nui o ka plasma concentrations o Ramelteon i pale i ka pono o ka hoʻololi ʻana.ʻO ka hoʻokomo pūʻolo, akā naʻe, e mālama i nā maʻi e pili ana i ka hui pū ʻana me ka potent CYP3A4 a me CYP2C9 inhibitors.Ma muli o ka hopena o nā hoʻokolohua lapaʻau, ʻo ka nui o Ramelteon i ʻōlelo ʻia he 8mg i lawe ʻia i loko o 30 mau minuke o ka moe.Ma kahi o ka mālama ʻana i ka hui pū ʻana me nā inhibitor CYP, ʻaʻole pono e hoʻohana ʻia i nā mea maʻi me ka maʻi hepatic koʻikoʻi.ʻO nā hanana ʻino, i ʻike ʻia ma 5% o nā mea maʻi i nā haʻawina lāʻau lapaʻau, he somnolence, dizziness, nausea, luhi, headache, and insomnia.